Oxidative stress and pathological changes after coronary artery interventions

Journal of the American College of Cardiology

Volumn 61, Issue 14, 2013, Pages 1471-1481

  Juni, Rio P ^a   Duckers, Henricus J ^b   Vanhoutte, Paul M ^c   Virmani, Renu ^d   Moens, An L ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d CVPATH INSTITUTE   (United States)

Author keywords

bare metal stent(s); drug eluting stent(s); endothelial dysfunction; nitric oxide synthase; percutaneous coronary intervention; reactive oxygen species; superoxide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ASCORBIC ACID; CANDESARTAN; CARVEDILOL; CERIVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE P38; NEBIVOLOL; NITRIC OXIDE; PACLITAXEL; PENTAERYTHRITYL TETRANITRATE; PROBUCOL; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUCCINOBUCOL; UMIROLIMUS; ZOTAROLIMUS;

ANTIOXIDANT ACTIVITY; ARTICLE; BARE METAL STENT; BIOAVAILABILITY; DISEASE ASSOCIATION; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; HUMAN; IN-STENT RESTENOSIS; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 84875786784     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.11.068     Document Type: Review

References (117)

1. V.W.T. Liu, P.L. Huang Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice Cardiovasc Res 77 2008 19 29
2. K. Bedard, K. Krause The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology Physiol Rev 87 2007 245 313
3. I. Al Ghouleh, N.K.H. Khoo, U.G. Knaus Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling Free Rad Biol Med 51 2011 1271 1288
4. J.F. Turrens Mitochondrial formation of reactive oxygen species J Physiol 552 2003 335 344
5. W. Armstead, R. Mirro, D. Busija, C. Leffler Postischemic generation of superoxide anion by newborn pig brain Am J Physiol Heart Circ Physiol 255 1988 H401 H403
6. X. Zhang, X. Min, C. Li Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27 Hypertension 55 2010 1412 1417
7. J. Yun, P. Rocic, Y.F. Pung Redox-dependent mechanisms in coronary collateral growth: the 'redox window' hypothesis Antiox Redox Signal 11 2009 1961 1974
8. K. Szocs, B. Lassegue, D. Sorescu Upregulation of Nox-based NAD (P) H oxidases in restenosis after carotid injury Arterioscler Thromb Vasc Biol 22 2002 21 27
9. G. Kochiadakis, D. Arfanakis, M. Marketou Oxidative stress changes after stent implantation: a randomized comparative study of sirolimus-eluting and bare metal stents Int J Cardiol 142 2009 33 37
10. 2-production in the pig coronary artery Circulation 96 1997 3593 3601
11. Y. Shi, R. Niculescu, D. Wang, S. Patel, K. Davenpeck, A. Zalewski Increased NAD (P) H oxidase and reactive oxygen species in coronary arteries after balloon injury Arterioscler Thromb Vasc Biol 21 2001 739 745
12. N. Ohashi, A. Matsumori, Y. Furukawa Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury Arterioscler Thromb Vasc Biol 20 2000 2521 2526
13. S. Janssens, D. Flaherty, Z. Nong Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats Circulation 97 1998 1274
14. O. Varenne, S. Pislaru, H. Gillijns Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs Circulation 98 1998 919 926
15. K. Ohtani, K. Egashira, Y. Ihara Angiotensin II type 1 receptor blockade attenuates in-stent restenosis by inhibiting inflammation and progenitor cells Hypertension 48 2006 664 670
16. L. Pendyala, J. Li, T. Shinke Endothelium-dependent vasomotor dysfunction in pig coronary arteries with paclitaxel-eluting stents is associated with inflammation and oxidative stress J Am Coll Cardiol Intv 2 2009 253 262
17. J. Alexandre, Y. Hu, W. Lu, H. Pelicano, P. Huang Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species Cancer Res 67 2007 3512 3517
18. G. Varbiro, B. Veres, F. Gallyas Direct effect of Taxol on free radical formation and mitochondrial permeability transition Free Radic Biol Med 31 2001 548 558
19. A. Jabs, S. Göbel, P. Wenzel Sirolimus-induced vascular dysfunction: increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation J Am Coll Cardiol 51 2008 2130 2138
20. 2 for platelet-derived growth factor signal transduction Science 270 1995 296 299
21. K.K. Griendling, G.A. FitzGerald Oxidative stress and cardiovascular injury Part II: animal and human studies Circulation 108 2003 2034 2040
22. A. Farb, A.P. Burke, F.D. Kolodgie, R. Virmani Pathological mechanisms of fatal late coronary stent thrombosis in humans Circulation 108 2003 1701 1706
23. P. Grewe, T. Deneke, A. Machraoui, J. Barmeyer, K. Müller Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen J Am Coll Cardiol 35 2000 157 163
24. Z. Chen, J. Keaney, E. Schulz Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury Proc Natl Acad Sci U S A 101 2004 13014 13019
25. A. Farb, G. Sangiorgi, A. Carter Pathology of acute and chronic coronary stenting in humans Circulation 99 1999 44 52
26. T. Inoue, T. Kato, Y. Hikichi Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening Thromb Haemost 95 2006 43
27. S.O. Marx, T. Jayaraman, L.O. Go, A.R. Marks Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells Circ Res 76 1995 412 417
28. M.V. Blagosklonny, Z. Darzynkiewicz, H.D. Halicka Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells Cell Cycle 3 2004 1050 1056
29. A. Kastrati, A. Dibra, J. Mehilli Predictive factors of restenosis after coronary implantation of sirolimus-or paclitaxel-eluting stents Circulation 113 2006 2293 2300
30. G. Nakazawa, F. Otsuka, M. Nakano The pathology of eoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
31. M.T. Castagna, G.S. Mintz, B.O. Leiboff The contribution of mechanical problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions Am Heart J 142 2001 970 974
32. M. Sabate, M.A. Costa, K. Kozuma Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy Circulation 101 2000 2467 2471
33. R. Koster, D. Vieluf, M. Kiehn Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis Lancet 356 2000 1895 1897
34. A. Farb, D.K. Weber, F.D. Kolodgie, A.P. Burke, R. Virmani Morphological predictors of restenosis after coronary stenting in humans Circulation 105 2002 2974 2980
35. H. van Beusekom, D. Whelan, S. Hofma Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries J Am Coll Cardiol 32 1998 1109 1117
36. M. Hamilos, M. Ostojic, B. Beleslin Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion J Am Coll Cardiol 51 2008 2123 2129
37. D. Shin, P. Kim, K. Seung Drug-eluting stent implantation could be associated with long-term coronary endothelial dysfunction Int Heart J 48 2007 553 567
38. M. Togni, L. Räber, R. Cocchia Local vascular dysfunction after coronary paclitaxel-eluting stent implantation Int J Cardiol 120 2007 212 220
39. H. Ota, M. Eto, J. Ako Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation J Am Coll Cardiol 53 2009 2298 2305
40. A. Lerman, E. Eeckhout Coronary endothelial dysfunction following sirolimus-eluting stent placement: should we worry about it? Eur Heart J 27 2006 125 126
41. S. Fuke, K. Maekawa, K. Kawamoto Impaired endothelial vasomotor function after sirolimus-eluting stent implantation Circ J 71 2007 220 225
42. R. Ross Rous-Whipple Award Lecture Atherosclerosis: a defense mechanism gone awry Am J Pathol 143 1993 987 1002
43. T. Inoue, K. Croce, T. Morooka, M. Sakuma, K. Node, D.I. Simon Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis J Am Coll Cardiol Intv 4 2011 1057 1066
44. M. Joner, A. Finn, A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
45. G. Nakazawa, A.V. Finn, M. Joner Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients Circulation 118 2008 1138 1145
46. T. Palmerini, G. Biondi-Zoccai, D.D. Riva Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
47. K.T. Khaw, S. Bingham, A. Welch Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study Lancet 357 2001 657 663
48. E.B. Rimm, M.J. Stampfer, A. Ascherio, E. Giovannucci, G.A. Colditz, W.C. Willett Vitamin E consumption and the risk of coronary heart disease in men N Engl J Med 328 1993 1450 1456
49. H.D. Sesso, J.E. Buring, W.G. Christen Vitamins E and C in the prevention of cardiovascular disease in men JAMA 300 2008 2123
50. S. Yusuf, G. Dagenais, J. Pogue, J. Bosch, P. Sleight Vitamin E supplementation and cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 154
51. G. Nunes, D. Sgoutas, R. Redden Combination of vitamins C and E alters the response to coronary balloon injury in the pig Arterioscler Thromb Vasc Biol 15 1995 156
52. J.E. Schneider, B.C. Berk, M.B. Gravanis Probucol decreases neointimal formation in a swine model of coronary artery balloon injury A possible role for antioxidants in restenosis Circulation 88 1993 628 637
53. T. Yokoyama, K. Miyauchi, T. Kurata, H. Sato, H. Daida Effect of probucol on neointimal thickening in a stent porcine restenosis model Jpn Heart J 45 2004 305 313
54. J.C. Tardif, G. Cote, J. Lesperance Probucol and multivitamins in the prevention of restenosis after coronary angioplasty N Engl J Med 337 1997 365 372
55. M. Yokoi, M. Daida, M. Kuwabara Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial J Am Coll Cardiol 30 1997 855 862
56. J. Rodes, G. Cote, J. Lesperance Prevention of restenosis after angioplasty in small coronary arteries with probucol Circulation 97 1998 429 436
57. G.L. Nunes, A.C. Abizaid, M.P. Theodoro Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study Am Heart J 152 2006 914.e1 914.e7
58. M. Sekiya, J. Funada, K. Watanabe, M. Miyagawa, H. Akutsu Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis Am J Cardiol 82 1998 144 147
59. T. Wakeyama, H. Ogawa, H. Iida Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial Circ J 67 2003 519 524
60. J. Watt, R. Wadsworth, S. Kennedy, K. Oldroyd Pro-healing drug-eluting stents: a role for antioxidants? Clin Sci 114 2008 265 273
61. K. Hayashi, M. Shimizu, H. Ino Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG Clin Sci 107 2004 175 182
62. S. Parthasarathy Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein Use of a new water-soluble probucol derivative J Clin Invest 89 1992 1618
63. J.C. Tardif, J. Gregoire, L. Schwartz Effects of AGI-1067 and probucol after percutaneous coronary interventions Circulation 107 2003 552 558
64. M. Oelze, A. Daiber, R.P. Brandes Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats Hypertension 48 2006 677 684
65. H. Mollnau, E. Schulz, A. Daiber Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells Arterioscler Thromb Vasc Biol 23 2003 615 621
66. M.A.W. Broeders, P.A. Doevendans, B.C.A.M. Bekkers Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta-adrenergic receptor-mediated nitric oxide production Circulation 102 2000 677 684
67. J.E. Toblli, G. Cao, C. Rivas Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats J Hyperten 28 2010 1007
68. P.W. Serruys, D.P. Foley, B. Hofling Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European carvedilol atherectomy restenosis (EUROCARE) trial Circulation 101 2000 1512 1518
69. J.C. Tardif, J. Gregoire, P.L. Lallier Prevention of restenosis with antioxidants: mechanisms and implications Am J Cardiovasc Drugs 2 2002 323 334
70. W. Kim, M.H. Jeong, K.S. Cha Effect of anti-oxidant (carvedilol and probucol) loaded stents in a porcine coronary restenosis model Jpn Circ J 69 2004 101 106
71. H.K. Kim, Y.J. Hong, M.H. Jeong Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease Korean J Int Med 26 2011 41
72. A. Warnholtz, G. Nickenig, E. Schulz Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system Circulation 99 1999 2027 2033
73. A.U. Klingbeil, S. John, M.P. Schneider, J. Jacobi, R. Handrock, R.E. Schmieder Effect of AT1 receptor blockade on endothelial function in essential hypertension Am J Hyperten 16 2003 123 128
74. B. Hornig, U. Landmesser, C. Kohler Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase Circulation 103 2001 799 805
75. J.S. Powell, J.P. Clozel, R. Muller Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury Science 245 1989 186
76. D.P. Faxon Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril J Am Coll Cardiol 25 1995 362 369
77. P. Serruys, W. Rutsch, N. Danchin Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial Circ (Baltimore) 86 1992 100 110
78. M. Igarashi, A. Hirata, H. Yamaguchi Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats Hypertension 38 2001 1255 1259
79. D.P. Wilson, L. Saward, P. Zahradka, P. Kee Cheung Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model Cardiovasc Res 42 1999 761
80. O. Yoshida, H. Hirayama, M. Nanasato, T. Watanabe, T. Murohara The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance Am Heart J 149 2005 e1 e6
81. J. Kramer, R.G. Ruf, S. Schmidt The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial-A Multicenter Study of AT1-Receptor Blocker Therapy in Coro J Invasive Cardiol 20 2008 205 210
82. A.H. Wagner, T. Kohler, U. Rockschloss, I. Just, M. Hecker Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation Arterioscler Thromb Vasc Biol 20 2000 61 69
83. T. Takayama, A. Wada, T. Tsutamoto Contribution of vascular NAD (P) H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor Jpn Circ J 68 2004 1067
84. S. Wassmann, U. Laufs, A.T. Baumer HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species Hypertension 37 2001 1450 1457
85. K. Shinozaki, Y. Nishio, K. Ayajiki Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD (P) H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production J Cardiovasc Pharmacol 49 2007 122
86. S.M. Chang, N. Yazbek, N.M. Lakkis Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome Catheter Cardiovasc Interv 62 2004 193 197
87. M. Nishino, S. Hoshida, H. Kato Preprocedural statin administration can reduce thrombotic reaction after stent implantation Jpn Circ J 72 2008 232
88. K. Miyauchi, T. Kasai, T. Yokayama Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model Jpn Circ J 72 2008 832
89. R. Wu, S. Duchemin, M.A. Laplante, J. De Champlain, H. Girouard Cyclo-oxygenase-2 knockout genotype in mice is associated with blunted angiotensin II-induced oxidative stress and hypertension Am J Hyperten 24 2002 1239 1244
90. B. Jorgensen, S. Simonsen, K. Endresen Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES) J Am Coll Cardiol 35 2000 592 599
91. S. Schuhmacher, M. Oelze, F. Bollmann Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy Diabetes 60 2011 2608 2616
92. G. Kojda, D. Stein, E. Kottenberg, E.M. Schnaith, E. Noack In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits J Cardiovasc Pharmacol 25 1995 763
93. S. Dikalov, B. Fink, M. Skatchkov, E. Bassenge Comparison of glyceryl trinitrate-induced with pentaerythrityl tetranitrate-induced in vivo formation of superoxide radicals: effect of vitamin C Free Radic Biol Med 27 1999 170 176
94. B. Halliwell The wanderings of a free radical Free Radic Biol Med 46 2009 531 542
95. U. Milman, S. Blum, C. Shapira Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype Arterioscler Thromb Vasc Biol 28 2008 341 347
96. L. Mauri, W. Hsieh, J.M. Massaro, K.K.L. Ho, R. D'Agostino, D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
97. J. Daemen, P. Wenaweser, K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
98. S. Hanson, T. Hutsell, L. Keefer, D. Mooradian, D. Smith Nitric oxide donors: a continuing opportunity in drug design Adv Pharmacol 34 1995 383 398
99. S. Kaul, R. Makkar, M. Nakamura Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO: an ex vivo porcine arteriovenous shunt study Circulation 94 1996 2228 2234
100. M. Reynolds, M. Frost, M. Meyerhoff Nitric oxide-releasing hydrophobic polymers: preparation, characterization, and potential biomedical applications Free Radic Biol Med 37 2004 926 936
101. M. Kushwaha, J. Anderson, C. Bosworth A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices Biomaterials 31 2009 1502 1508
102. A. de Waha, S. Cassese, D.W. Park Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials Clin Res Cardiol 2012 1 7
103. E. Kedhi, K.S. Joesoef, E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
104. G.W. Stone, M. Midei, W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
105. G.W. Stone, A. Rizvi, W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
106. E. Grube, L. Buellesfeld BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease Expert Rev Med Devices 3 2006 731 741
107. S. Windecker, P.W. Serruys, S. Wandel Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
108. E. Grube, K.E. Hauptmann, L. Buellesfeld, V. Lim, A. Abizaid Six-month results of a randomized study to evaluate safety and efficacy of a Biolimus A9 eluting stent with a biodegradable polymer coating EuroIntervention 1 2005 53 57
109. J. Wykrzykowska, P. Serruys, P. Buszman The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS) EuroIntervention 7 2011 789 795
110. G.G. Stefanini, B. Kalesan, P.W. Serruys Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
111. J. Mehilli, R.A. Byrne, A. Wieczorek Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
112. R.A. Byrne, A. Kastrati, S. Kufner Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) trial Eur Heart J 30 2009 2441 2449
113. M. Hamilos, J. Sarma, M. Ostojic Interference of drug-eluting stents with endothelium-dependent coronary vasomotion circulation Cardiovasc Interv 1 2008 193 200
114. F. Sharif, S.O. Hynes, R. Cooney Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis Mol Ther 16 2008 1674 1680
115. L. Brito, S. Chandrasekar, M. Amiji, S. Little Non-viral eNOS gene delivery and transfection with stents for the treatment of restenosis Biomed Eng Online 9 2010 56
116. Y. Zhang, J. Bissing, L. Xu, A. Ryan, S. Martin, F. Miller Nitric oxide synthase inhibitors decrease coronary sinus-free radical concentration and ameliorate myocardial stunning in an ischemia-reperfusion model* 1 J Am Coll Cardiol 38 2001 546 554
117. Y. Zhang, S.P. Janssens, K. Wingler, H.H.H.W. Schmidt, A.L. Moens Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy Am J Physiol Heart Circ Physiol 301 2011 H634 H646